We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

127 hedge funds and large institutions have $598M invested in Enanta Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 50 increasing their positions, 36 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

238% more call options, than puts

Call options by funds: $1.44M | Put options by funds: $426K

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

39% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 36

32% more capital invested

Capital invested by funds: $454M → $598M (+$144M)

4% more funds holding

Funds holding: 122 → 127 (+5)

0.83% more ownership

Funds ownership: 66.11% → 66.95% (+0.83%)

Holders
127
Holders Change
+5
Holders Change %
+4.1%
% of All Funds
3.17%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
19
Increased
50
Reduced
36
Closed
12
Calls
$1.44M
Puts
$426K
Net Calls
+$1.01M
Net Calls Change
+$775K

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$25M
2
FCM
Farallon Capital Management
California
+$16.6M
3
Franklin Resources
Franklin Resources
California
+$8.04M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$4.12M
5
NI
Numeric Investors
Massachusetts
+$3.86M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$17.5M
2
GTC
Ghost Tree Capital
New York
-$7.2M
3
AC
Armistice Capital
New York
-$6.27M
4
SCM
Stonepine Capital Management
Oregon
-$4.11M
5
KAM
Krensavage Asset Management
New York
-$3.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
26
Opaleye Management
Massachusetts
$4.68M – – –
AllianceBernstein
27
AllianceBernstein
Tennessee
$4.31M +$896K +22,300 +32%
Goldman Sachs
28
Goldman Sachs
New York
$3.93M +$13.3K +331 +0.4%
QI
29
QS Investors
New York
$3.58M -$55.6K -1,383 -2%
Charles Schwab
30
Charles Schwab
California
$2.64M +$113K +2,803 +5%
New York State Common Retirement Fund
31
New York State Common Retirement Fund
New York
$2.31M +$496K +12,340 +33%
Prudential Financial
32
Prudential Financial
New Jersey
$2.18M +$19.7K +490 +1%
VRS
33
Virginia Retirement Systems
Virginia
$2.07M -$872K -21,700 -33%
TCIM
34
TIAA CREF Investment Management
New York
$1.92M -$75K -1,867 -4%
New York State Teachers Retirement System (NYSTRS)
35
New York State Teachers Retirement System (NYSTRS)
New York
$1.8M +$12.1K +300 +0.8%
MVM
36
McClain Value Management
Connecticut
$1.78M -$1.09M -27,233 -42%
BIM
37
Bogle Investment Management
Massachusetts
$1.78M +$1.53M +37,967 New
Bank of Montreal
38
Bank of Montreal
Ontario, Canada
$1.65M +$1.42M +35,256 New
Morgan Stanley
39
Morgan Stanley
New York
$1.59M +$127K +3,155 +10%
USAA
40
United Services Automobile Association
Texas
$1.58M -$563K -14,000 -29%
VEA
41
Virtus ETF Advisers
New York
$1.51M – – –
AL
42
AJO LP
Pennsylvania
$1.5M +$1.29M +32,167 New
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$1.5M +$35K +870 +3%
CS
44
Credit Suisse
Switzerland
$1.5M +$134K +3,343 +12%
FIM
45
Freedom Investment Management
Connecticut
$1.41M -$58.8K -1,463 -5%
WMSA
46
Weiss Multi-Strategy Advisers
New York
$1.4M – – –
TA
47
Teachers Advisors
New York
$1.3M – – –
GC
48
Guggenheim Capital
Illinois
$1.3M +$64.5K +1,605 +6%
Barclays
49
Barclays
United Kingdom
$1.25M -$134K -3,325 -11%
Legal & General Group
50
Legal & General Group
United Kingdom
$1.22M +$35.2K +876 +3%
1
2
3 4 5

ENTA Hedge Fund Activity: Q3 2017 in Review

127 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2017, worth a combined $598M — up 32% from $454M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ENTA positions and 12 closed out — a net gain of 7 holders — while 50 added to existing stakes and 36 trimmed.

The largest buyer was Invesco, adding an estimated $25M. The largest seller was Millennium Management, exiting entirely with an estimated $17.5M sold.

  • 127 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2017, up from 122 in Q2 2017.
  • Funds reported $598M of Enanta Pharmaceuticals stock for Q3 2017, up 32% quarter-over-quarter.
  • 19 funds opened new Enanta Pharmaceuticals positions in Q3 2017 and 12 closed out, a net change of +7 holders.
  • The largest Enanta Pharmaceuticals buyer in Q3 2017 was Invesco, an estimated $25M added.
  • The largest Enanta Pharmaceuticals seller in Q3 2017 was Millennium Management, an estimated $17.5M sold.

Based on aggregated 13F filings for Q3 2017.